Tamoxifen Resistance Trumped and Oral Selective Estrogen Receptor Degraders Arrive

Predictive tests, to refine the estrogen receptor assay, for the adjuvant treatment of breast cancer with tamoxifen and oral Selective Estrogen Receptor Degraders (SERDs) are required.  A splice variant of the corepressor NCOR2, BQ2313636.1 predicts tamoxifen resistence to adjuvant tamoxifen and AZ9496, the first oral SERD, completes phase one studies

from Cancer via ola Kala on Inoreader https://ift.tt/2Hi7LMp
via IFTTT